Scrutica
REGENERON PHARMACEUTICALSfinancials and operating footprint — geographic revenue split, segment mix, capex / FCF / buyback history, industry placement — sourced from licensed-database extracts and SEC EDGAR, joined to the supply-chain graph through the industry classification.
Where REGENERON PHARMACEUTICALS sits in the compute supply chain: where its revenue comes from, what it spends capital on, and which counterparties move money in and out of the door.
Each hop carries its data source, source URL (where one exists), as-of date, and confidence label on the same line as the parent name. When two sources name different parents for the same hop, both sit on the page as alternates — the walker does not pick a winner.
No licensed-database enrichment loaded for this entity — geographic revenue, segments, capital allocation, and industry classification are absent. Coverage rules in the methodology.
Starting entity — the walker climbs from here, following documented parent / subsidiary edges in the ownership substrate.
Chain-of-title terminates at REGENERON PHARMACEUTICALS. No further parent is documented — for a public filer that means UBO is the dispersed float; for a state-linked entity it means the chain has reached the sovereign apex.